当前位置: X-MOL 学术Am. J. Gastroenterol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Refinement of Hy's Law using the Drug-Induced Liver Injury Network Database.
The American Journal of Gastroenterology ( IF 8.0 ) Pub Date : 2024-10-18 , DOI: 10.14309/ajg.0000000000003145
A Sidney Barritt,Paul H Hayashi,Andrew A Stolz,Huiman Barnhart,Jay H Hoofnagle,

BACKGROUND Hyman Zimmerman observed that hepatocellular (HC) drug-induced liver injury (DILI) with jaundice had a mortality rate of ≥10% (Hy's Law). Hy's Law does not specify the timing of liver tests nor the definition of HC DILI versus cholestatic or mixed (C/M) DILI. We aimed to assess the validity of Hy's Law in the prospective Drug-Induced Liver Injury Network (DILIN) cohort. METHODS Drugs with ≥10 confirmed DILI cases with jaundice were analyzed. Four permutations of Hy's Law were applied: R≥ 5 using initial (1) or peak (2) ALT, AST and Alk P levels, and the FDA associated criteria of ALT or AST ≥ 3x ULN with Alk P ≤ 2x ULN using initial (3) or peak values (4). Mortality was death or liver transplant adjudicated to be due to DILI. RESULTS Using initial R values, mortality was 11.1% for HC vs 2.0% for C/M (p<0.001); using peak R values, mortality was 10.3% vs 1.6% (p<0.001). Using FDA associated definition, mortality was 7.9% vs 3.9% (p=0.04) using initial values and 7.9% vs 3.0% (p=0.01) using peak values. Using initial R values, drugs that frequently caused HC injury generally had mortality rates ≥ 10%; while drugs that typically caused C/M injury all had rates <10%. Occasional agents that caused HC injury with jaundice were associated with low mortality. CONCLUSIONS Initial R values were the most reliable means of identifying Hy's Law cases. There were some drugs that caused HC injury with jaundice but with mortality rates <10%. Refinement of Hy's Law is warranted.

中文翻译:


使用药物诱导肝损伤网络数据库改进 Hy 定律。



背景 Hyman Zimmerman 观察到肝细胞 (HC) 药物诱导的肝损伤 (DILI) 伴黄疸的死亡率为 ≥10% (Hy's Law)。Hy 定律没有具体说明肝脏检查的时间,也没有规定 HC DILI 与胆汁淤积或混合 (C/M) DILI 的定义。我们旨在评估 Hy 定律在前瞻性药物诱导肝损伤网络 (DILIN) 队列中的有效性。方法 分析 ≥10 例确诊 DILI 黄疸病例的药物。应用了 Hy 定律的四种排列:R≥ 5 使用初始 (1) 或峰值 (2) ALT、AST 和 Alk P 水平,以及 FDA 的 ALT 或 AST ≥ 3x ULN 与 Alk P ≤ 2x ULN 使用初始 (3) 或峰值 (4)。死亡率是死亡或肝移植被判定为 DILI 所致。结果 使用初始 R 值,HC 的死亡率为 11.1%,C/M 为 2.0% (p<0.001);使用峰值 R 值,死亡率为 10.3% 和 1.6% (p<0.001)。使用 FDA 相关定义,使用初始值的死亡率为 7.9% vs 3.9% (p=0.04),使用峰值的死亡率为 7.9% vs 3.0% (p=0.01)。使用初始 R 值,经常导致 HC 损伤的药物的死亡率通常≥ 10%;而通常导致 C/M 损伤的药物的发生率均为 <10%。偶尔导致 HC 损伤伴黄疸的药物与低死亡率相关。结论 初始 R 值是识别 Hy 定律案例的最可靠方法。有一些药物导致 HC 损伤伴有黄疸,但死亡率为 <10%。对 Hy 定律的改进是有道理的。
更新日期:2024-10-18
down
wechat
bug